Remicade (infliximab) denied as not FDA-approved for this use by UnitedHealthcare?

This UnitedHealthcare commercial policy (effective 02.01.2026) addresses the use of infliximab products including Avsola, Inflectra, Remicade, and Renflexis , and applies to billing codes J1745, Q5103, Q5104, and Q5121 . UHC designates Avsola and Inflectra as the preferred infliximab products for UHC commercial plans , and members already on Remicade, Renflexis, or other non-preferred infliximab product will be required to change therapy to Inflectra or Avsola unless they meet the exception criteria . To obtain Remicade specifically, the policy requires documentation of a trial of at least 14 weeks of Inflectra or Avsola resulting in minimal clinical response, OR a physician attestation that in their clinical opinion the clinical response would be expected to be superior with Remicade than with Inflectra and Avsola , or alternatively documentation of intolerance, contraindication, or adverse event to the preferred biosimilars with a physician attestation that the same event would not be expected to occur with Remicade . Indication-specific criteria require disease-appropriate step therapy — for example, ankylosing spondylitis requires history of failure to two NSAIDs at maximally indicated doses, each used for at least 4 weeks, unless contraindicated, or prior treatment with a systemic targeted immunomodulator FDA-approved for ankylosing spondylitis ; plaque psoriasis requires greater than or equal to 3% body surface area involvement, or palmoplantar, facial, or genital involvement plus failure of a topical therapy. Patients must not be receiving infliximab in combination with another systemic targeted immunomodulator (e.g., adalimumab, Cimzia, Enbrel, Orencia, Simponi, Rinvoq, Xeljanz) for treatment of the same indication , and dosing must be according to FDA-labeled dosing for the indication . Prior authorization is required, and the policy notes the patient must not have FDA-labeled contraindications and must be tested for latent TB per prescribing information, with treatment begun if positive .

- For forced biosimilar switching: cite the ACR position that coverage for non-preferred products should consider patient-specific exception criteria, and ACR has urged UHC to allow existing patients to continue on their current medication and proposed additional exception criteria for patient protection ; also reference AGA's negotiated exceptions that adult patients currently on induction of Remicade for less than 18 months will not be required to switch, and adult patients having a flare of active disease, and hence are not stable, will not be required to switch - For pediatric IBD denials of Remicade continuation: cite United's agreement to modify its coverage policy to allow pediatric patients 16 years of age and younger currently on Remicade to remain on Remicade if that is the recommendation of the treating physician , supported by NASPGHAN/AGA/ACG/ASGE consensus - For step therapy in Crohn's disease: cite the ACG Clinical Guideline for Crohn's Disease in Adults and AGA Care Pathway recommending early anti-TNF therapy for moderate-to-severe disease and high-risk features (fistulizing, stricturing, perianal, young age at diagnosis) — aligns with UHC's own high-risk criteria language - For step therapy in rheumatoid arthritis: cite the 2021 ACR Guideline for RA Treatment supporting biologic DMARDs (including TNFi) after inadequate response to methotrexate; for ankylosing spondylitis cite the 2019 ACR/SAA/SPARTAN AS Guideline strongly recommending TNFi after NSAID failure - For plaque psoriasis criteria: cite the AAD-NPF 2019 Guidelines of Care for the Management of Psoriasis with Biologics supporting infliximab for moderate-to-severe disease and special-site involvement (palmoplantar, facial, genital), matching UHC's BSA/special-site criteria - For non-medical switching/efficacy concerns: cite the NOR-SWITCH randomized controlled trial (Jørgensen et al., Lancet 2017) demonstrating non-inferiority of CT-P13 biosimilar to originator infliximab — but conversely, a documented loss of response or infusion reaction on a biosimilar meets UHC's own exception pathway for Remicade - For concomitant biologic denial: clarify in the appeal that the patient is transitioning therapies (not on simultaneous biologics) with appropriate washout, addressing UHC's combination-therapy exclusion language

## Why UnitedHealthcare May Deny Remicade (Infliximab) as "Not FDA-Approved"

Remicade (infliximab) holds FDA approval for a defined set of inflammatory indications, but UnitedHealthcare may issue a "not FDA-approved" denial when: the submitted diagnosis code does not map to a labeled indication in UHC's system; the claim is for a use that is technically off-label (even if supported by guidelines); or an administrative coding error caused a mismatch between the product, the indication, and the benefit type (medical vs. pharmacy benefit). Because infliximab is administered by infusion and billed under the medical benefit in most cases, benefit-category mismatches are a particular source of these denials.

## Why This Denial Is Appealable

If the use is on-label, the denial is almost always correctable through documentation — it is an administrative fix, not a clinical argument. If the use is off-label but guideline-supported, UHC is required to evaluate whether the use meets its evidence standard for off-label coverage, and that determination can be challenged through the external review process with an independent clinical reviewer who applies objective standards, not UHC's internal policy.

## Federal Appeal Framework

• Internal appeal: Under ACA §2719 and ERISA §503, UHC must provide the specific basis for the "not FDA-approved" finding and allow you to respond. The denial letter must include the criteria applied.
• External review: After a final internal denial, escalate to an independent external reviewer within approximately four months. This reviewer applies evidence-based clinical standards and is not bound by UHC's formulary or policy.
• Expedited review: Available when the patient's condition is urgent. File simultaneously with the standard appeal.

## Documentation to Gather

1. Current FDA prescribing information — obtain the full current label for Remicade (infliximab). Attach the specific indication section that corresponds to the patient's diagnosis. If the use is on-label, this is the primary correction document. 2. Accurate diagnosis and coding confirmation — review the submitted ICD and CPT/HCPCS codes. Confirm the diagnosis code matches a labeled indication and that the product code is correct for branded infliximab (not a biosimilar code). 3. Prescriber letter — confirms the specific diagnosis, the FDA-approved indication being treated, and the clinical basis for infliximab as the appropriate agent. 4. For off-label use: A summary of the relevant professional society guideline (e.g., ACR, AGA, or applicable specialty society) endorsing this use, prepared by the prescriber or their office.

## Criteria-Mapping Structure

| UHC / FDA Requirement | Documentation Response | |---|---| | FDA-labeled indication (copy from label) | Patient diagnosis + ICD code + chart confirmation | | Correct product code billed | Claim review — CPT/HCPCS code used | | Benefit category (medical vs. pharmacy) | Confirm infusion billed under medical benefit | | Off-label evidence standard (if applicable) | Guideline reference + prescriber letter |

For on-label denials, a corrected claim or a concise appeal letter with the label attached frequently resolves the denial without requiring a full multi-document submission.